GlobeNewswire Inc | Apr 29, 2021 08:00AM EDT

April 29, 2021

DUBLIN, Ireland, April 29, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 10, 2021, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2021.

To access the conference call, investors are invited to dial (877) 407-9716 (U.S. and Canada) or (201) 493-6779 (International). The conference ID number is 13719428. A live audio webcast can be accessed by visiting the investor relations section of the Companys website, www.avadel.com. A replay of the webcast will be archived on Avadels website for 90 days following the event.

Contacts:

Investor Contacts Tom McHughChief Financial OfficerPhone: (636) 449-1843Email: tmchugh@avadel.com Tim McCarthyLifeSci Advisors, LLCPhone: (212) 915-2564Email: tim@lifesciadvisors.com

Media ContactPatrick BurseyLifeSci Communications, LLCPhone: (646) 970-4688Email: pbursey@lifescicomms.com